应对乳腺癌的临床复杂性。
Tackling the clinical complexity of breast cancer.
作者信息
Lenti Marco Vincenzo, Sottotetti Federico, Corazza Gino Roberto
机构信息
First Department of Internal Medicine, San Matteo Hospital Foundation; University of Pavia, Pavia, Italy.
Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
出版信息
Drugs Context. 2022 Jun 28;11. doi: 10.7573/dic.2022-2-3. eCollection 2022.
Abstract
Clinical complexity (CC) is an increasingly recognized feature of internal medicine patients who are often characterized by complex needs determined by both biological (i.e. intrinsic to the patient or disease biology) and non-biological (i.e. socioeconomic, cultural, environmental, behavioural) factors. Breast cancer, one of the most common malignancies worldwide, certainly represents an example of a complex disease. Nonetheless, the concept itself of CC and its possible determinants in breast cancer have been poorly addressed. We herein provide our view about the possible factors triggering CC, the key issues of CC and the related unmet needs in breast cancer.
摘要
临床复杂性（CC）是内科患者中一个日益受到认可的特征，这些患者通常具有由生物学因素（即患者或疾病生物学固有的因素）和非生物学因素（即社会经济、文化、环境、行为因素）共同决定的复杂需求。乳腺癌是全球最常见的恶性肿瘤之一，无疑是一种复杂疾病的典型例子。然而，CC这一概念本身及其在乳腺癌中的可能决定因素却很少得到探讨。我们在此阐述我们对于引发乳腺癌临床复杂性的可能因素、临床复杂性的关键问题以及相关未满足需求的看法。
相似文献
1
Tackling the clinical complexity of breast cancer.应对乳腺癌的临床复杂性。
Drugs Context. 2022 Jun 28;11. doi: 10.7573/dic.2022-2-3. eCollection 2022.
2
Bringing complexity into clinical practice: An internistic approach.将复杂性带入临床实践：一种内科方法。
Eur J Intern Med. 2019 Mar;61:9-14. doi: 10.1016/j.ejim.2018.11.009. Epub 2018 Dec 6.
3
A consensus for the development of a vector model to assess clinical complexity.
Intern Emerg Med. 2017 Dec;12(8):1313-1318. doi: 10.1007/s11739-017-1709-6. Epub 2017 Jul 14.
4
Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).大分子拥挤现象：化学与物理邂逅生物学（瑞士阿斯科纳，2012年6月10日至14日）
Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 2.
5
The association of health-related quality of life with unmet supportive care needs and sociodemographic factors in low-income Latina breast cancer survivors: a single-centre pilot study.低收入拉丁裔乳腺癌幸存者的健康相关生活质量与未满足的支持性护理需求及社会人口因素的相关性：单中心试点研究。
Disabil Rehabil. 2019 Dec;41(26):3151-3156. doi: 10.1080/09638288.2018.1485179. Epub 2018 Jul 27.
6
Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.乳腺癌幸存者的未满足需求很常见，多学科护理未得到充分利用：生存需求评估项目。
Breast Cancer. 2021 Mar;28(2):289-297. doi: 10.1007/s12282-020-01156-2. Epub 2020 Sep 14.
7
Responding to vulnerable patients with multimorbidity: an interprofessional team approach.应对多病共存的脆弱患者：一种跨专业团队方法。
BMC Prim Care. 2022 Mar 30;23(1):62. doi: 10.1186/s12875-022-01670-6.
8
Addressing the Evidence Gap in Stroke Rehabilitation for Complex Patients: A Preliminary Research Agenda.解决复杂患者脑卒中康复中的证据空白：初步研究议程。
Arch Phys Med Rehabil. 2018 Jun;99(6):1232-1241. doi: 10.1016/j.apmr.2017.08.488. Epub 2017 Sep 22.
9
The Role of Artificial Intelligence in Managing Multimorbidity and Cancer.人工智能在管理多重疾病和癌症中的作用。
J Pers Med. 2021 Apr 19;11(4):314. doi: 10.3390/jpm11040314.
10
Complexity in internal medicine wards: A novel screening method and implications for management.
J Eval Clin Pract. 2018 Feb;24(1):285-292. doi: 10.1111/jep.12875. Epub 2018 Jan 10.
引用本文的文献
1
The meaning of trust along the treatment pathway of women with breast cancer: a mixed-methods study among cancer survivors.乳腺癌女性治疗过程中信任的意义：一项针对癌症幸存者的混合方法研究
BMC Womens Health. 2025 Jan 15;25(1):25. doi: 10.1186/s12905-024-03540-y.
2
Hypermethylation of the Gene Body in Is Involved in Breast Cancer Cell Proliferation and Is a Potential Blood-Based Biomarker for Early Detection and a Poor Prognosis.基因体的过度甲基化与乳腺癌细胞增殖有关，并且是一种潜在的基于血液的早期检测和不良预后的生物标志物。
Biomolecules. 2024 May 12;14(5):571. doi: 10.3390/biom14050571.
3
Towards Agility in Breast Cancer Treatment Principles as Adopted from Agile Software Engineering.借鉴敏捷软件工程的乳腺癌治疗原则中的敏捷性
J Multidiscip Healthc. 2024 Mar 23;17:1315-1341. doi: 10.2147/JMDH.S449465. eCollection 2024.
4
Health-related quality of life and clinical complexity of a real-life cohort of patients with advanced HR/HER2 breast cancer treated with CDK4/6 inhibitors and endocrine therapy.使用CDK4/6抑制剂和内分泌治疗的晚期HR/HER2乳腺癌真实队列患者的健康相关生活质量和临床复杂性。
Drugs Context. 2023 Jun 20;12. doi: 10.7573/dic.2023-1-7. eCollection 2023.
5
Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.新辅助化疗治疗的乳腺癌患者免疫炎症生物标志物的预后潜力
Cancers (Basel). 2022 Oct 27;14(21):5287. doi: 10.3390/cancers14215287.
本文引用的文献
1
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).关于老年乳腺癌患者管理的最新建议：欧洲乳腺肿瘤学会（EUSOMA）和国际老年肿瘤学会（SIOG）的联合文件。
Lancet Oncol. 2021 Jul;22(7):e327-e340. doi: 10.1016/S1470-2045(20)30741-5. Epub 2021 May 14.
2
Diagnostic Reasoning in Internal Medicine. Cynefin Framework Makes Sense of Clinical Complexity.内科诊断推理。辛菲框架解读临床复杂性。
Front Med (Lausanne). 2021 Apr 22;8:641093. doi: 10.3389/fmed.2021.641093. eCollection 2021.
3
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.Sacituzumab Govitecan 治疗转移性三阴性乳腺癌。
N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485.
4
Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018.乳腺癌患者的健康相关生活质量：2008 年至 2018 年的综述回顾。
Health Qual Life Outcomes. 2020 Oct 12;18(1):338. doi: 10.1186/s12955-020-01591-x.
5
Clinical complexity and hospital admissions in the December holiday period.十二月假期期间的临床复杂性和住院治疗。
PLoS One. 2020 Jun 11;15(6):e0234112. doi: 10.1371/journal.pone.0234112. eCollection 2020.
6
Age-related disparities in older women with breast cancer.老年女性乳腺癌的年龄相关差异。
Adv Cancer Res. 2020;146:23-56. doi: 10.1016/bs.acr.2020.01.003. Epub 2020 Feb 29.
7
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.恩美曲妥珠单抗治疗既往 HER2 阳性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.
8
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.阿贝西利联合氟维司群治疗激素受体阳性、HER2 阴性乳腺癌的疗效：内分泌治疗进展后总生存的影响——MONARCH 2 随机临床试验
JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782.
9
Breast cancer.乳腺癌。
Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2.
10
Palbociclib in metastatic breast cancer: current evidence and real-life data.帕博西尼治疗转移性乳腺癌：当前证据与真实世界数据
Drugs Context. 2019 Jul 16;8:212579. doi: 10.7573/dic.212579. eCollection 2019.
Zotero 插件